Anders Hovland

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12136615/publications.pdf

Version: 2024-02-01

623734 552781 39 725 14 26 citations g-index h-index papers 40 40 40 1116 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Increased risk of peripheral artery disease in persons with familial hypercholesterolaemia: a prospective registry study. European Journal of Preventive Cardiology, 2022, 28, e11-e13.	1.8	6
2	Subjects with familial hypercholesterolemia have lower aortic valve area and higher levels of inflammatory biomarkers. Journal of Clinical Lipidology, 2021, 15, 134-141.	1.5	6
3	High-Density Lipoprotein Subfractions: Much Ado about Nothing or Clinically Important?. Biomedicines, 2021, 9, 836.	3.2	9
4	Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: Results from the randomized GutHeart trial. EBioMedicine, 2021, 70, 103511.	6.1	34
5	Loss of statin treatment years during pregnancy and breastfeeding periods in women with familial hypercholesterolemia. Atherosclerosis, 2021, 335, 8-15.	0.8	23
6	Relationship between Clinical Symptoms and Magnetic Resonance Imaging in Temporomandibular Disorder (TMD) Patients Utilizing the Piper MRI Diagnostic System. Journal of Clinical Medicine, 2021, 10, 4698.	2.4	5
7	Comparison of cytokine changes in three different lipoprotein apheresis systems in an ex vivo whole blood model. Journal of Clinical Apheresis, 2020, 35, 104-116.	1.3	3
8	Anti-inflammatory effects of non-statin low-density lipoprotein cholesterol-lowering drugs: an unused potential?. Scandinavian Cardiovascular Journal, 2020, 54, 274-279.	1.2	9
9	Association of Low-Density Lipoprotein Cholesterol With Risk of Aortic Valve Stenosis in Familial Hypercholesterolemia. JAMA Cardiology, 2019, 4, 1156.	6.1	31
10	Addition of marine omega-3 fatty acids to statins in familial hypercholesterolemia does not affect inÂvivo or inÂvitro endothelial function. Journal of Clinical Lipidology, 2019, 13, 762-770.	1.5	10
11	Intensive lipid lowering therapy reduces large, but not small, dense low-density lipoprotein particles measured by gel electrophoresis, in elderly patients with atrial fibrillation. European Journal of Preventive Cardiology, 2019, 26, 2017-2018.	1.8	1
12	LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia. Journal of Clinical Lipidology, 2019, 13, 279-286.	1.5	39
13	Risk of Ischemic Stroke and Total Cerebrovascular Disease in Familial Hypercholesterolemia. Stroke, 2019, 50, 172-174.	2.0	12
14	Granulocyte and monocyte CD11b expression during plasma separation is dependent on complement factor 5 (C5) – an <i>ex vivo</i> study with blood from a C5â€deficient individual. Apmis, 2018, 126, 342-352.	2.0	1
15	Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study. Transfusion and Apheresis Science, 2018, 57, 91-96.	1.0	16
16	Bariatric surgery improves lipoprotein profile in morbidly obese patients by reducing LDL cholesterol, apoB, and SAA/PON1 ratio, increasing HDL cholesterol, but has no effect on cholesterol efflux capacity. Journal of Clinical Lipidology, 2018, 12, 193-202.	1.5	31
17	CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?. Diseases (Basel,) Tj ETQq1 1 0.78	4314 rgB1 2.5	「/Qverlock 10
18	Design of the GutHeart—targeting gut microbiota to treat heart failure—trial: a Phase II, randomized clinical trial. ESC Heart Failure, 2018, 5, 977-984.	3.1	39

#	Article	IF	CITATIONS
19	Increased risk of heart failure and atrial fibrillation in heterozygous familial hypercholesterolemia. Atherosclerosis, 2017, 266, 69-73.	0.8	16
20	Bariatric surgery reduces fasting total fatty acids and increases n-3 polyunsaturated fatty acids in morbidly obese individuals. Scandinavian Journal of Clinical and Laboratory Investigation, 2017, 77, 628-633.	1.2	9
21	Calculating the 30-day Survival Rate in Acute Myocardial Infarction: Should we Use the Treatment Chain or the Hospital Catchment Model?. Heart International, 2017, 12, heartint.500023.	1.4	1
22	LDL apheresis activates the complement system and the cytokine network, whereas PCSK9 inhibition with evolocumab induces no inflammatory response. Journal of Clinical Lipidology, 2016, 10, 1481-1487.	1.5	10
23	Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol. Atherosclerosis, 2016, 251, 119-123.	0.8	15
24	The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis. Atherosclerosis, 2015, 241, 480-494.	0.8	90
25	A vital role for complement in heart disease. Molecular Immunology, 2014, 61, 126-134.	2.2	61
26	Three different LDL apheresis columns efficiently and equally reduce lipoprotein(a) concentrations in patients with familial hypercholesterolemia and small apolipoprotein(a) particles. Transfusion and Apheresis Science, 2012, 46, 73-76.	1.0	15
27	Complement profile and activation mechanisms by different LDL apheresis systems. Acta Biomaterialia, 2012, 8, 2288-2296.	8.3	18
28	Patient tolerance regarding different low-density lipoprotein apheresis columns: Frequent minor side effects and high patient satisfaction. Journal of Clinical Lipidology, 2011, 5, 45-49.	1.5	7
29	Side effects in LDL apheresis: types, frequency and clinical relevance. Clinical Lipidology, 2011, 6, 717-722.	0.4	6
30	Gated SPECT Offers Improved Interobserver Agreement Compared With Echocardiography. Clinical Nuclear Medicine, 2010, 35, 927-930.	1.3	8
31	Hematologic and hemostatic changes induced by different columns during LDL apheresis. Journal of Clinical Apheresis, 2010, 25, 294-300.	1.3	21
32	No evidence of impaired endothelial function or altered inflammatory state in patients with familial hypercholesterolemia treated with statins. Journal of Clinical Lipidology, 2010, 4, 288-292.	1.5	14
33	Selective whole blood lipoprotein apheresis to prevent pancreatitis in drug refractory hypertriglyceridemia. JOP: Journal of the Pancreas, 2010, 11, 467-9.	1.5	4
34	Different inflammatory responses induced by three LDLâ€lowering apheresis columns. Journal of Clinical Apheresis, 2009, 24, 247-253.	1.3	35
35	Feasibility of Using Tissue Doppler Velocities in Stress Echo during Upright Bicycle Exercise. Echocardiography, 2009, 26, 1041-1049.	0.9	0
36	Transient ST elevation due to coronary spasm in a young woman. Canadian Journal of Cardiology, 2009, 25, e141-e142.	1.7	4

Anders Hovland

#	Article	IF	CITATIONS
37	Reversible ischemia in Wellens' syndrome. Journal of Nuclear Cardiology, 2006, 13, e13-e15.	2.1	9
38	EEG should be performed during induced hypothermia. Resuscitation, 2006, 68, 143-146.	3.0	94
39	Pericardial Effusion in a Patient with Lymphangioleiomyomatosis. Scandinavian Journal of Infectious Diseases, 2004, 36, 521-522.	1.5	3